Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|May 24, 2026
Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancerAlessandra Raimondi, Gabriele Tinè, Valerie Boige, et al.
Frontiers in Oncology|February 21, 2022
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future PerspectiveMichele Prisciandaro, Maria Antista, Alessandra Raimondi, et al.
European Urology Oncology|September 23, 2019
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT StudyGiuseppe Procopio, Giulia Apollonio, Francesco Cognetti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trialsAlessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
The Oncologist|December 18, 2020
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based AnalysisFilippo Pietrantonio, Giovanni Fucà, Daniele Rossini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 StudyGiovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
The Oncologist|August 6, 2021
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated MelanomaLorenza Di Guardo, Giovanni Randon, Francesca Corti, et al.
British Journal of Cancer|November 23, 2021
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino studyPaolo Manca, Salvatore Corallo, Sara Lonardi, et al.
The Oncologist|April 10, 2020
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future TrialsSalvatore Corallo, Giovanni Fucà, Federica Morano, et al.
Clinical Colorectal Cancer|September 1, 2023
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal OriginFilippo Ghelardi, Alessandra Raimondi, Federica Morano, et al.
Pageof 8